

Delivering trusted cancer insights, from screening to survivorship



Hereditary cancer screening is critical, **yet many eligible patients remain untested**

5% - 10%

Approximately

inherited mutations1

80%

of women who meet NCCN criteria for hereditary breast and ovarian cancer screening have NOT had testing²

Estimated


95%

of individuals with Lynch syndrome **are** unaware of it³

Your goals remain unchanged . . .



Provide the **highest standard of care** to meet your patients' expectations





Obtain accurate and timely diagnostic information to improve patient prognosis



Identify inherited health risks and support early action, which could lead to **positive outcomes**



Manage healthcare efficiently through high-quality diagnostic tests and treatments

Clear genetic insights can empower informed decisions. Is your diagnostic partner keeping up?

Excellence in hereditary cancer screening

We are committed to providing enhanced access to hereditary cancer solutions, empowering patients and providers to understand cancer risk and inform treatment and prognosis when applicable. Our full-service approach streamlines the journey—from screening and ordering to pre-authorization, sample analysis, and result interpretation—ensuring a seamless and supportive experience at every step.



Complete portfolio of hereditary cancer tests, from multi-gene panels to single-site tests



MDs, PhDs, and genetic counselors available for test consultation and results interpretation

Need additional assistance?

Direct and accessible genetic support is available from board-certified genetic counselors, medical geneticists, and medical directors daily from 8:30 AM to 8:00 PM EST. Call **1.866.GENE.INFO** (**1.866.436.3463**) for answers, reports, results interpretation, and post-test consultation.

Leadership in genetic testing provides stability



40+ years

of genetic testing experience

 Peer-to-peer consultation with medical and scientific experts, including genetic counselors

Reliable support and services

- Quanum Solutions® and EHR integration make it easy to order tests and get results when you need them
- In-network with most major health plans, with supplemental financial assistance programs available



Dedicated genetics customer service line—1.866.GENE.INFO. (1.866.436.3463)

Support for your patients

- A network with more than 2,250 patient service centers
- Out-of-pocket limit of \$200 for qualified patients through our supplemental financial assistance program
- Qualified tests provided at no charge for uninsured or underinsured patients who qualify
- · Ability to accept a variety of sample types



Bucca



Saliva



Blood

Comprehensive test menu

- Comprehensive hereditary cancer panel (66 genes)
- · Guideline-based hereditary cancer panel (32 genes)



We offer a robust portfolio of diseaseand condition-specific hereditary cancer tests.

Visit **TestDirectory.QuestDiagnostics.com** to find a specific test.

The power of Quest

A consolidated solution that brings seamless access along the cancer care continuum . . .



combined with unmatched support services beyond testing



Going beyond the test to

operationalize your precision medicine vision

- 700+ medical professionals on staff, including subspecialized pathologists, oncologists, PhDs, and genetic counselors
- Superlative logistics, including ~4,000 courier vehicles and 20+ aircraft
- Integration with LIS and EMRs
- Easy-to-use Quanum[®]
 Lab Services Manager
 that streamlines workflow
- Dedicated Genomic Client Services team that serves as a comprehensive resource for genetic testing questions from patients and providers

Committed to the future of cancer care

by making investments in strategic innovations and data optimization

- Collaboration with leading academic institutions
- Contributions to thought leadership in peer-reviewed publications
- Ability to process a wide range of sample types from whole blood to saliva, including specialized options like skin fibroblasts
- Dedicated Variant IQ team continuously that investigates variants of uncertain significance for resolution

Improving the patient journey

by championing accessibility and affordability

- In-network with ~90% of insured lives nationwide
- Preferred lab of Aetna®, Horizon®, UnitedHealthcare®, and many others
- Dedicated pre-authorization team ensuring optimal service and seamless patient access to tailored financial assistance options
- Removing barriers to care by offering financial assistance programs

Hereditary cancer complete genetic testing menu

Comprehensive Hereditary Cancer Panel

Includes **66 genes**, including emerging genes, to provide deeper genetic insights to help make more informed decisions about your patient's care

Test code	Genes included	
38600	APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, DICER1, EGFR, EPCAM, FANCA, FANCC, FANCM, FH, FLCN, GALNT12, GREM1, HOXB13, MAX, MEN1, MET, MITF, MLH1, MRE11 (MRE11A), MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2 PMS2, POLD1, POLE, POT1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2	

Guideline-Based Hereditary Cancer Panel

32 genes that provide clinically actionable results for hereditary cancers, including moderate-to-high risk for breast, colon, prostate, uterine, melanoma, and other hereditary cancers

Test code	Genes included	
38611	APC, ATM, AXIN2, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A (p16,p14), CHEK2, EPCAM, GREM1, H0XB13, MLH1, MSH2, MSH3,	
	MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53	

Hereditary Breast Cancer Panel

Tests for variants in 18 genes predominantly associated with breast, prostate, and other tissue cancers

Test code	Genes included	
38621	ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53	

Hereditary Colorectal Cancer Panel

Tests for variants in 20 genes associated with increased risk for colorectal cancer

Test code	Genes included	
38631	APC, AXIN2, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53	

Hereditary Endocrine Cancer Panel

Tests for variants in 12 genes associated with increased risk for paragangliomas, pheochromocytomas, and endocrine cancers

Test code	Genes included	
38641	FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL	

BRCA Panel Plus

Detects variants in ${\bf 7}$ genes associated specifically with breast cancer

Test code	Genes included
92587	BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53

Additional hereditary cancer risk tests

We offer syndrome-specific tests that analyze genes that can be associated with different cancer syndromes, including Lynch Syndrome, Hereditary Breast and Ovarian Cancer Syndrome, Familial Adenomatous Polyposis (FAP), and others.

Test code	Test name	Genes included
91461	Lynch Syndrome Panel (5 genes)	MLH1, MSH2, MSH6, PMS2, EPCAM (del/dup only)
38651	Nevoid Basal Cell Carcinoma (NBCCS) (Gorlin) Syndrome Panel (<i>PTCH1</i> , <i>SUFU</i>)	PTCH1, SUFU
38661	Tuberous Sclerosis Complex Panel (TSC1, TSC2)	TSC1, TSC2
94053	Juvenile Polyposis Panel (BMPR1A, SMAD4)	BMPR1A, SMAD4
93945	Hereditary Cancer Single Site(s)	APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A (p16, p14), CHEK2, DICER1, EGFR, EPCAM, FANCA, FANCC, FANCM, FH, FLCN, GALNT12, GREM1, HOXB13, MAX, MEN1, MET, MITF, MLH1, MRE11 (MRE11A), MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2
See description column	Single-gene tests*	APC - 93797, ATM - 38802, BAP1 - 38803, BLM - 38804, CDH1 - 92568, CDKN2A - 93939, CHEK2 - 93940, EPCAM/MSH2 - 91471, FH - 38805, FLCN - 38806, HOXB13 - 38807, MEN1 - 93942, MITF - 38808, MLH1 - 91460, MSH6 - 91458, MUTYH - 93944, NF1 - 93941, PALB2 - 92571, PMS2 - 91457, PTEN - 92566, RET - 93796, SMARCA4 - 38809, STK11 - 92565, TP53 - 92560, VHL - 93943

^{*} All panel components are available individually.

For a complete list of our current hereditary cancer risk tests, please visit: TestDirectory.QuestDiagnostics.com

We have a variety of tools to help you collect your patient's family history.



Explore our website for patient resources, including tools to gather family history and a video to guide patients through the genetic testing consent process. Visit QuestDiagnostics.com/CancerGenetics





Better quality of life for your patients can start with better access to testing

We ensure critical testing is always within your patients' reach.



Broad coverage for enhanced access

We're in network with most major health plans and also have preferred lab network status. We strive to deliver pricing at the time of service for patients and prevent surprise bills.

90% of patients who meet testing criteria through their insurance will have no out-of-pocket cost



Access to genetic counselors

Our genomic science specialists are board-certified by the American Board of Genetic Counseling and can assist with test selection, result interpretation, VUS reclassification, and post-test consultation services at no additional charge.

Our specialists can be reached at 1.866.GENE.INFO. (1.866.436.3463)



Advanced testing that's affordable

Our Specialty Testing Services team manages prior authorizations and helps navigate reimbursements to save you time and make our family of genetic tests more accessible.

We will notify you and/or your patient prior to testing if the out-of-pocket cost is estimated over \$100 for all BRCA-related tests. For further questions, please contact us at 1.855.422.5181 or PreAuthorization@QuestDiagnostics.com



Experience the power of Quest. Call 1.866.GENE.INFO or visit QuestDiagnostics.com/CancerGenetics to learn more.

Test codes may vary by location. Please contact your local laboratory for more information.

Image content features models and is intended for illustrative purposes only.

References:

- 2. Childers CP, Childers KK, Maggard-Gibbons M, et al. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800-3806. doi: 10.1200/JC0.2017.73.6314
- 3. National Cancer Institute. Cancer Moonshot Blue Ribbon Panel Report 2016. Accessed March 7, 2025. https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/history/blue-ribbon-panel-report-2016.pdf

QuestDiagnostics.com